Business
IBM/OpenAI logos
(Bronson Stamp for Sherwood Media)

OpenAI is IBM

IBM was first to market in a new area, but lost to fierce competition.

Jack Raines

Who are the biggest cloud players today? Amazon, Google, and Microsoft, three companies all worth more than $2 trillion in market capitalization. All three were early to the cloud, launching AWS, Google Cloud, and Azure in 2006, 2008, and 2008, respectively.

Yet another technology company, IBM, rolled out “the cloud” four years before AWS.

In 2002, IBM announced a new service called Linux Virtual Services, which would allow customers to run their own software on IBM computers in its data centers. Clients would be charged per usage instead of having to sign long-term contracts. In a 2002 Wall Street Journal story, IBM executive James Corgel said the company saw “a huge opportunity going forward,” estimating that the on-demand computing market would be worth between $100 billion and $150 billion in five years. Corgel didn’t know just how right he was: in 2024, AWS alone had annualized revenue exceeding $100 billion. And the market is still growing.

Yet despite IBM’s early entrance to the cloud market, it lost. In 2023, IBM generated $62 billion in revenue. Meanwhile, AWS alone generated $91 billion for Amazon. While IBM may’ve been the first to launch “the cloud,” it failed to win the market because it couldn’t find product market fit. Today, IBM is worth roughly the same valuation it had in 1999 and 2000.

In the future, when we look back at all these AI companies, we may end up viewing OpenAI as the IBM of the AI wave: the first mover that failed to capture all the economic value.

There are a few reasons why.

First, AI-scaling laws appear to be providing diminishing returns. Until November, the consensus was that AI would continue to improve as computing power increased. But OpenAI, Google, and Anthropic have begun to see smaller marginal returns on further increasing compute. As a result, OpenAI’s new model, Orion, fell short of the company’s desired performance.

On top of slowing performance gains, customers don’t need frontier-edge models to accomplish their goals now that “normal,” cheaper models are quite powerful. Most companies just need an AI model to do a few specific tasks, and super-powerful, all-reaching models are unnecessarily large and expensive. 

Even if OpenAI’s Orion model proves to be the most powerful model on the market, its utility to customers may be only marginally higher than a much cheaper alternative.

When you combine plateauing improvements with a plateauing customer need for improvements, models quickly grow commoditized as they converge to the same performance level. When models are commoditized, customers will choose the cheapest option, eroding OpenAI’s margins.

Fintech unicorn Ramp provides a good example of this commoditization in practice. It’s been using responses from OpenAI’s GPT-4 to help it fine-tune open-source models from Mistral and Meta, and the resulting custom models are cheaper and better than GPT-4.

Another risk facing OpenAI is a talent outflow: thanks to tender offers from outside investors, early employees have sold their now very valuable OpenAI stakes, and at least nine key executives have stepped down. In a competitive AI marketplace, where Meta and Musk are gunning for you, competition is cutthroat and losing top talent could be fatal.

That brings us to the last point: competition is fierce. Meta, xAI, and Anthropic are spending billions to keep scaling their AI models, and open-source models, which companies can fine-tune to address their own needs more cheaply, continue to improve. As baseline AI tech keeps getting better, customers will likely opt for cost efficiency over anything else, in a shift that doesn’t bode well given that OpenAI’s models are more expensive to run than open-source alternatives.

It’s possible that in 20 years we’ll live in a world where AI is ubiquitous, but OpenAI won’t be the big winner because the technology got commoditized. OpenAI is worth $157 billion today. Could it, like IBM, still be worth the same valuation in 20 years? Maybe.

Read the other arguments for OpenAI's future here.

More Business

See all Business
business

Hims to stop offering copy of Wegovy pill following FDA scrutiny

Hims & Hers said it has decided to stop offering its newly launched copycat version of Novo Nordisk’s Wegovy pill, after the telehealth company drew criticism from the Food and Drug Administration. 

“Since launching the compounded semaglutide pill on our platform, we’ve had constructive conversations with stakeholders across the industry. As a result, we have decided to stop offering access to this treatment,” Hims wrote on X.

Shares of Hims are down double digits in premarket trading on Monday, while Novo Nordisk ADRs are up more than 6% as of 5:20 a.m. ET.

On Friday afternoon, the FDA said it would take “decisive steps” to restrict GLP-1 compounding. Department of Health and Human Services General Counsel Mike Stuart said on social media Friday he had referred Hims to the Department of Justice “for investigation for potential violations by Hims of the Federal Food, Drug, and Cosmetic Act and applicable Title 18 provisions.”

Hims launched the product last week, a seeming copy of a recently released and patented drug, which immediately drew fire from Novo Nordisk and regulators.

Shares of Hims are down double digits in premarket trading on Monday, while Novo Nordisk ADRs are up more than 6% as of 5:20 a.m. ET.

On Friday afternoon, the FDA said it would take “decisive steps” to restrict GLP-1 compounding. Department of Health and Human Services General Counsel Mike Stuart said on social media Friday he had referred Hims to the Department of Justice “for investigation for potential violations by Hims of the Federal Food, Drug, and Cosmetic Act and applicable Title 18 provisions.”

Hims launched the product last week, a seeming copy of a recently released and patented drug, which immediately drew fire from Novo Nordisk and regulators.

Hims oral semaglutide

Hims, long flying under regulators’ radar, finally strikes a nerve with its Wegovy pill copy

It’s unclear if the pill Hims is selling works or if the FDA will allow it.

$1.3M

There’s still plenty of money to be made in brainrot. The top 1,000 Roblox creators earned an average of $1.3 million in 2025 — up 50% from the year prior — according to CEO Dave Baszucki on the company’s fourth-quarter earnings call.

Roblox paid out $1.5 billion to creators last year, meaning its top 1,000 creators took home about 87% of the total pool.

Like other creator economy giants, Roblox rewards its biggest creators for their contributions to user engagement. Creator-made titles like “Grow a Garden” and “Steal a Brainrot” substantially boosted playing time over the course of the year. In September, the company increased its developer exchange rate, or the ratio of in-game currency to cash payout, by 8.5%.

Texas Governor Abbott And Google Make Economic Development Announcement In Midlothian

Alphabet could buy some pretty huge businesses with the amount of money it plans to spend this year

AI outlays have gone full nut-nut. Even Google, one of the most capital-efficient businesses of all time in its heyday, is spending like there’s no tomorrow.

Tom Jones2/6/26

Latest Stories

Sherwood Media, LLC produces fresh and unique perspectives on topical financial news and is a fully owned subsidiary of Robinhood Markets, Inc., and any views expressed here do not necessarily reflect the views of any other Robinhood affiliate, including Robinhood Markets, Inc., Robinhood Financial LLC, Robinhood Securities, LLC, Robinhood Crypto, LLC, or Robinhood Money, LLC.